Multiple myeloma (MM) is a clonal neoplasm of plasma cells which offers an excellent model to study multistep molecular oncogenesis. In 20-25% of primary tumors and cell lines examined, cyclin D1 is overexpressed due to the translocation t(11;14)(q13;q32). We have characterized cyclin-dependent kinase inhibitor p15 (CDKN2B), p16 (CDKN2A) and p18 (CDKN2C) deletions in cyclin D1-expressing and non-expressing MM cell lines. p18 was found to be frequently deleted (38%); in some cases p18 deletions coexisted with hemizygous p16 deletion. To examine the function of p18 as a putative tumor suppressor in myeloma cells, a zinc-inducible p18 construct was stably transfected into KMS12, a MM cell line with biallelic p18 and monoallelic p16 deletions as well as cyclin D1 overexpression. Ectopic expression of p18 caused 40-45% growth suppression as determined by trypan blue exclusion and MTS assays. p18 induction also resulted in apoptosis, suggesting that inhibition of the cyclin D1/CDK/pRb pathway in these tumor cells could be a crucial step toward the induction of tumor regression via apoptotic cell death. This cell cycle pathway is thus frequently mutated and provides a potentially novel target for gene therapeutic or pharmacologic approaches to human myeloma.
Introduction
Multiple myeloma (MM) is a clonal plasma cell neoplasm that provides an excellent model to study multistep molecular oncogenesis. A chromosomal translocation involving the IgH locus, most frequently into a switch region, is a nearly universal event in MM cell lines and primary tumor samples. 1 Molecular events contributing to karyotypic instability in a B lymphocyte may initially lead to a monoclonal gammopathy of undetermined significance (MGUS, 'benign' monoclonal gammopathy) and evolve to smouldering myeloma, overt MM, and in some cases to extramedullary progression or plasma cell leukemia. 1 In 20-25% of MM cell lines and tumors examined, cyclin D1 (CCND1) is brought under the influence of immunoglobulin heavy chain (IgH) chain enhancer and promoter elements by a chromosomal translocation at Bcl-1/CCND1 breakpoints via the translocation t(11;14)(q13;q32). This leads to cyclin D1 overexpression and suggests that disruption of cell cycle regulatory elements may be pathogenetically important in this malignancy. 2 Cyclin D1 functions as an oncogene in some systems, in part by promoting cyclin D1-CDK phosphorylation of pRb. 3, 4 During the mid-G1 phase of the cell cycle, the catalytic subunit of CDK forms a complex with its regulatory sub-unit cyclin D1 and phosphorylates the tumor suppressor pRb and related proteins, releasing sequestered E2F and leading to the activation of genes required for DNA replication and S phase progression. The activity of cyclin D1-CDK4 and cyclin D1-CDK6 holoenzymes is regulated at multiple levels including cyclin abundance, cyclin D1-CDK4 and cyclin D1-CDK6 assembly, dephosphorylation of inhibitory sites, CAK/cyclin H1 activation of the complex by phosphorylation of the conserved threonine-160 residue, and 1:1 stoichiometric interaction of CDKs with the INK4 family CDKIs. [5] [6] [7] [8] The INK4 family members are tumor suppressor genes comprised of the proteins p16 (CDKN2A), p15 (CDKN2B), p18 (CDKN2C), and p19 (CDKN2D) that negatively regulate CDK4 and CDK6 activity. [9] [10] [11] [12] The functional similarity of all four genes is reflected in their protein structure; each contains highly conserved ankyrin domains suggesting all may have a role in regulating proliferation.
p18 predominantly binds to CDK6 and, to a lesser extent, to CDK4 and inactivates their kinase activity. 9, 10 Furthermore, p18 can efficiently block CDK6 phosphorylation by CAK/cyclin H1. 8 IL-6, a cytokine implicated in myeloma pathogenesis, induces p18 expression in IgG-bearing B lymphocytes and correlates with cell cycle arrest, differentiation and cell death. 13 Together, these findings suggest CDKI p18 status may provide useful insights into the molecular mechanisms of myeloma pathogenesis.
In order to assess cell cycle regulatory mutations in human myeloma, we have analyzed MM-derived tumor cell lines with or without cyclin D1 overexpression for CDKI p15, p16 and p18 gene deletions and correlated the association with D1 expression. The KMS12 myeloma cell line, which has homozygous p18 and hemizygous p16 deletions and overexpresses cyclin D1, was used to analyze complementation of p18 function. We generated KMS12-derived cell lines transfected with an inducible p18 expression vector, thus re-establishing the G1 restriction point. We report here that ectopic p18 induction causes growth inhibition and apoptosis in the KMS12 multiple myeloma cell line, suggesting that this dysregulated cell cycle pathway may serve as a target for myeloma therapy.
Materials and methods

Cell culture
The multiple myeloma cell line KMS12 was provided by Kimoto and colleagues to one of us (WMK). 14, 15 The Granta line was derived from a human mantle cell lymphoma and was a kind gift from DM Jadayel, 16 Institute of Cancer Research, Surrey, UK. Cells were grown at 37°C (5% CO 2 ) in RPMI 1640 media supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 2 mM/l L-glutamine, and 100 U/ml penicillin and 100 g/ml streptomycin. Stable KMS12 transfectants were maintained in growth medium supplemented with 450 g/ml G418 without penicillin and streptomycin supplementation.
Southern blot analysis
Genomic DNA was isolated from cultured cells and clinical samples using Qiagen Blood and Cell Culture DNA kit (Qiagen, Valencia, CA, USA). Ten micrograms of DNA were digested with EcoRI, fractionated on 0.7% agarose gels, denatured with 0.5 N NaOH, 1.5 mol/l NaCl, neutralized with 1 mol/l Tris-HCl pH 7.4, 1.5 mol/l NaCl, and transferred overnight with 20 × SSC (3 mol/l sodium chloride/3 mol/l sodium citrate) on to nylon membranes (Stratagene, La Jolla, CA, USA) and UV-crosslinked. cDNA probes for p15 (a gift from Dr David Beach, Cold Spring Harbor, Long Island, NY, USA), and p18 (a gift from Dr Y Xiong, UNC, Chapel Hill, NC, USA), were labeled via the random priming technique using the Ready-To-Go kit (Pharmacia Biotech, Piscataway, NJ, USA), and 50 Ci 32 P-CTP (specific activity 6000 Ci/mmole, NEN, Boston, MA, USA). The membranes were sequentially prehybridized and hybridized with 32 P-labeled probes in Quick Hyb solution at 68°C according to the manufacturer's instructions (Stratagene). The membranes were washed twice in 2 × SSC buffer and 0.1% (w/v) SDS at room temperature, followed by a third wash in 0.1 × SSC buffer and 0.1% (w/v) SDS at 60°C. Autoradiography was performed using Kodak XAR5 films (Eastman Kodak, Rochester, NY, USA) at −70°C with intensifying screens. Gene deletion was identified by decreased signal intensity relative to placental control DNA.
PCR analysis
DNA extracted from MM cell lines was analyzed by PCR to detect p18 gene deletions as previously described. 17 Primers used to amplify p18 exon 1, exon 2 A and B were as follows: P18-exon 1, 5Ј-CCTGATCGTCAGGACCCTAA-3Ј/5Ј-CCAA CCTGCAGCCGAGT-3Ј; p18-exon 2A, 5ЈAGGATTCTACCAT TTCTACTT-3Ј/5Ј-CTTCTTTGGCAGCCAAGTGC3Ј; p18-exon 2B, 5Ј-GACTTGCTGGAGTTTCAAGCTG3Ј/5ЈTTATTGAAGAT TTGTGGCTCCCCCA-3Ј. These primers cover the entire p18 coding region. All PCR reactions were carried out in a final volume of 100 l containing 500 ng DNA, 0.5 M each of primer, 400 M dNTPs, 1.0 mm Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl 2, 2.5 U Taq polymerase. PCR reactions were overlayed with two drops of mineral oil. PCR conditions used an initial denaturation for 3 min at 94°C, followed by 35 cycles of 1 min denaturation at 94°C, 1.5 min annealing at 58°C, extension for 2 min at 72°C, and final extension for 10 min. The PCR products were extracted with chloroform, and separated on 1.5% agarose or 10% non-denaturing polyacrylamide gels. Placental DNA was used in all reactions as a positive control for p18 amplification.
Stable transfections in KMS12
A full-length p18 cDNA containing the entire coding region of 507 bp (a gift from Dr Yue Xiong) was removed from pUC 118 plasmid backbone by cleavage with BamHI. The cDNA fragment was subcloned in the pMth-Neo eukaryotic expression vector which uses the zinc-inducible metallothionein I promoter to drive expression of a cloned cDNA. 18 The vector includes a neomycin cassette for selection. The vector also contains exons III and IV of the human beta-globin gene which provides splice donor and acceptor sites as well as a polyadenylation signal. The pMth-p18 expression vector was then transfected into exponentially growing KMS12 cells using the lipid reagent DMRIE-C (Life-Technologies, Gaithersburg, MD, USA) following the manufacturer's instructions. Negative control cell lines were generated using the pMth-Neo vector alone. Stable clones were selected by G418 resistance, then individually grown and analyzed for inducible expression of p18 mRNA. Of 79 neomycin-resistant clones examined, five (33 a-e) could be induced to express p18 with ZnCl 2 when added at a final concentration of 120 M to the exponentially growing cells.
Northern blot analysis
Total RNA was extracted from exponentially growing cells using the RNA-STAT 60 System (TEL-TEST, Friendswood, TX, USA). Ten micrograms of RNA was fractionated on 1% agarose gels containing 0.22 mol/l formaldehyde, and transferred with 20 × SSC buffer on to dura-Lon-UV membranes, and UVcross-linked. Prehybridization and hybridization with alpha-32 P CTP-labeled probe, and sequential washes of the membranes were performed as described above for Southern blot analysis. Autoradiography was done using Kodak XAR5 films at −70°C with intensifying screens, with semiquantitation of expression by comparison with positive (Granta cell line) and negative (KMS12 cell line) controls.
Immunoprecipitation and Western blotting
Cells were harvested and washed with PBS, left on ice for 30 min, then lysed in basic NP-40 lysing buffer supplemented with protease inhibitor cocktail, as described by Xiong and colleagues 19 for 30 min at 4°C. Nuclei and debris were removed by centrifugation at 12 000 r.p.m. for 10 min in an Eppendorf microcentrifuge model 5415 C. Protein concentration was determined using the BCA assay (Pierce, Rockford, IL, USA). One mg of protein was immunoprecipitated with 10 g monoclonal p18 Ab-1 (Neomarker, Fremont, CA, USA) at 4°C overnight, and 100 l of prewashed Protein A Agarose beads (Life-Technologies) were added for 2 h. The beads were recovered by centrifugation, washed with NP-40 lysis buffer four times and resolved by electrophoresis by SDS-PAGE on 15% polyacrylamide gels. Proteins were transferred to nitrocellulose membrane, and the blots were blocked with 5% nonfat dry milk-0.5% Tween-20 in phosphate buffered saline (PBS) solution with the primary antibody, monoclonal p18-Ab2 (Neomarker), in a 1:100 dilution for 1 h at room temperature. Following four washes with PBS-Tween 20, immune complexes were detected using horseradish-conjugated antirabbit antibody at a 1:10 000 dilution, and visualized by ECL (Amersham, Arlington Heights, IL, USA).
Cell proliferation
Cells were plated at a density of 1 × 10 5 /ml/well in duplicate in a 24-well plate. After 24 h of incubation at 37°C in a humidified atmosphere of 5% CO 2 and 95% air, cells were treated with or without ZnCl 2 for 0, 24, and 48 h. A 100 l aliquot of cell suspension was taken at the indicated times and counted with a hemocytometer by the trypan blue exclusion test.
Cell growth MTS assay
Cell viability was also measured by MTS Cell-Titer 96 AQ (Promega, Madison, WI, USA), a colorimetric method for determining the number of viable cells in proliferation or cytotoxicity assays. Cells were plated at a density of 1 × 10 5 /ml/well in triplicate overnight and treated with or without ZnCl 2 for 0, 24, and 48 h. A 100 l aliquot of cell suspension was taken at the indicated times and transferred to 96-well titer plates. Twenty microliters of MTS solution was added to each well and incubated at 37°C for 2 h. The intensity of the soluble brown formazan product, directly proportional to the number of viable cells, was measured by reading absorbance at 490 nm using a Titer Tek microplate reader (ICN Biochemicals, Irvine, CA, USA).
DNA fragmentation
Proliferating cells were plated at a density of 1 × 10 5 /ml in 15 ml Petri dishes, grown overnight, and treated or not treated with ZnCl 2 for 0, 18, 36, and 60 h. For the DNA fragmentation assay 20 cells were lysed in a buffer containing 1% NP-40 in 20 mM EDTA and 50 mM Tris-HCl (pH 7.5). The supernatant was recovered by centrifugation at 1600 g for 5 min, brought to 1% SDS and treated for 2 h with 5 g/l RNAse A at 56°C. Subsequently, Proteinase K was added and incubated at 37°C for 2 h. The lysate was precipitated using 0.5 volumes of 10 M ammonium acetate and 2.5 volumes of ethanol at −20°C for 1 h. Precipitated DNA was pelleted by centrifugation, resuspended in 1 × TE (10 mM Tris-HCl, pH 7.4 and 1 mM EDTA) and fractionated by electrophoresis on 1% agarose gels. DNA ladders were visualized by ethidium bromide staining.
Results
CDKI gene deletions in MM cell lines
Structural abnormalities of chromosome 1 are frequently detected in MM at diagnosis and have been correlated with more advanced or aggressive disease. 21 The p18 gene has been mapped to human chromosome 1p32. Although p18 deletions have been reported to be rare in human malignancy, [22] [23] [24] [25] [26] [27] cytogenic analysis has shown abnormalities of 1p32-36 in 16% of human MM as well as 14% of low-grade non-Hodgkin's lymphoma (NHL) and 12% of diffuse large cell lymphoma. To determine whether p18 may be a critical element of such deletions, to assess the correlation of such deletions, if any, with cyclin D1 translocation and overexpression, and to assess p18 as a candidate MM tumor suppressor gene, we examined by Southern blot analysis five cyclin D1-overexpressing and 11 cyclin D1-nonexpressing human MM cell lines for p15/p16 and p18 gene deletions. Each cyclin D1-expressing cell line had a karyotypic or cloned t(11;14) translocation. 2 Three of the five cell lines positive for cyclin D1 expression contained coexisting deletions of p15/p16 and p18, whereas three of 11 cyclin D1-negative Leukemia lines contained homozygous p18 deletions (Table 1, Figure  1a) . No p15/p16 deletions were identified by Southern blot in the eight cyclin D1-negative lines tested. PCR confirmed the frequency of p18 gene deletions in MM cell lines. PCR amplification of p18 exon 1 generated a clear band in cells with wild-type p18, whereas homozygous deletions were found in the cell lines KMS12, MM1, MY5, OPM2 (Figure 1b ) and SKMM2 (data not shown). As p18 deletions are rare in most human neoplasms and cell lines [22] [23] [24] [25] [26] [27] but have been identified in mantle cell lymphoma and some human myelomas, 21, 28, 29 these frequent deletions in MM cell lines suggest a pathogenic role via cell cycle dysregulation, either alone or in concert with cyclin D1 overexpression.
Inducible ectopic expression of p18 in KMS12
To examine the relevance of loss of p18 function in MM , we re-expressed the p18 gene in the KMS12 cell line, which is homozygous p18 null. We generated a full-length p18 cDNA in the eukaryotic expression plasmid pMTH-Neo, which uses a zinc-inducible metallothionein promoter, such that ectopic p18 expression is regulated by the addition of zinc chloride to the growth medium. Asynchronously proliferating KMS12 cells were transfected with the pMth-Neo vectors lacking or containing the p18 cDNA. Forty-eight hours later, transfectants were transferred into medium supplemented with G418. Clones resistant to G418 were selected and analyzed for Zninducible expression of p18 mRNA by Northern blot analysis. Five clones, 33a-33e, were identified that inducibly expressed p18 mRNA (Figure 2a and data not shown) . No clones were identified that expressed detectable amounts of p18 mRNA in the absence of ZnCl 2 . The mantle cell lymphoma line GRANTA, which has germline p18 by Southern blot, was used as a positive control for p18 RNA expression. Differing p18 transcripts are expressed in various tissues, indicating a tissuespecific regulation. 9 These transcript sizes reflect variations in the 5 prime untranslated region; 30 however, all transcripts encode the same protein. The endogenous transcripts Table 1 Analysis of cyclin D1 expression and CDK inhibitor p15/p16 and p18 deletions in human multiple myeloma cell lines Cell line D1 p15/p16 p18 expression
G, germline; 1 DEL, hemizygous deletion; DEL, homozygous deletion. Amplification of the 5Ј region of the ␤-globin gene (400 bp) served as a positive amplification control. PCR products were electrophoresed on 1.5% agarose gels and stained with ethidium bromide. Placental DNA was used as a positive p18 control.
expressed in the Granta cell line are 1.9 and 1.1 kb; the ectopically expressed p18 mRNA is 1.1 kb size and encodes the full-length protein. The pMth-Neo and KMS12 control lines did not express p18 mRNA, with or without zinc treatment (Figure 2a) . Based upon the results of multiple RNA blotting experiments, we estimate the abundance of p18 mRNA
Figure 2
Inducible expression of ectopic p18 mRNA and protein in the KMS12 multiple myeloma cell line clone 33a+. (a) Northern blot analysis of p18 mRNA isolated from KMS12, pMth-Neo (vectortransfected line), the mantle cell lymphoma line Granta (a positive control for endogenous p18 mRNA), and pMth-p18-transfected 33a cell lines, treated with (+) or without (−) zinc chloride for p18 induction. Total RNA was extracted from the cell lines indicated, separated on formaldehyde-agarose gels (10 g/lane), transferred on to nylon membranes and hybridized with a 32 P-labeled p18 cDNA probe. Autoradiographic exposure time was 4 h. Equal loading was confirmed by the amount of ribosomal RNA (not shown). (b) Immunoprecipitation Western blot analysis of p18 protein from KMS12, Granta, pMth-p18 (33a) and pMth-Neo (vector only) cell lines, treated with (+), and without (−) zinc chloride for p18 induction. Whole cell lysates were immunoprecipitated with p18 ab-1, separated by 15% SDSpolyacrylamide gel electrophoresis, immunoblotted, and probed with p18 ab-2. The 18 kDa p18 protein is detected in the Granta cells (lane 4) and in the zinc-induced 33a cells (lane 5). Lanes 1, protein molecular weight marker; 2, KMS12−; 3, KMS12+; 4, Granta; 5, 33a+; 6, 33a−; 7, pMth-Neo+; 8, pMmth-Neo−.
in the 33a+ (Zinc-induced) line to be 10 to 20-fold higher than that seen in exponentially growing Granta cells.
Expression of p18 protein was examined in the KMS12, pMth-Neo, and 33a (pMth-p18) cell lines with (+) or without (−) ZnCl 2 by immunoprecipitation followed by blotting with the p18-Ab1 monoclonal antibody. Whole cell extracts produced from 33a+ and Granta cell lines expressed detectable amounts of p18 protein after 18 h of induction with Zn. In contrast, KMS12 and the negative control pMTH-Neo did not contain inducible p18 protein. The ectopically induced p18 from the 33a+ cell line migrated at the same position as the endogenous p18 from Granta cells (Figure 2b ).
Ectopic expression of p18 inhibits KMS12 proliferation
To test the hypothesis that overexpression of cyclin D1 coupled with the loss of CDKI p18 deletion provides a growth advantage to the cells, we tested the effects of enforced p18 expression on cell growth. 1 × 10 5 cells/ml were plated and grown for 24 h followed by ZnCl 2 addition to induce p18 expression. A 100 l aliquot of cell suspension was removed from the culture plates for cell counts by trypan blue exclusion after 24 and 48 h of Zn treatment. After 24 h of p18 induction with ZnCl 2 treatment, cell proliferation was reduced to 40-45% of the uninduced controls (33a−), pMth-Neo and KMS12; the differences remained the same after 48 h (Figure 3 ). All the clones (33a-e) which expressed p18 mRNA in the presence of ZnCl 2 , exhibited the same growth inhibition patterns in the trypan blue cell counting proliferation assay (data not shown). Zinc treatment for 24 h had no inhibitory effect on proliferation of the KMS12 parental cells. Experiments to transfect the pMth-p18 vector into the cyclin D1−, p18 −/− OPM2 myeloma cell line were unsuccessful due to intrinsic resistance of the wild-type OPM2 cells to high concentrations of G418 and a resulting inability to select transfected clones.
We also examined the cell viability by the MTS assay of mitochondrial function. Similar to the cell-counting assay, cells were plated at a density of 1 × 10 5 and Zn was added after 24 h for p18 induction. A 100 l aliquot of cell suspension was removed from the culture plates at 24, 48, and 72 h of induction and assayed for viable cells. Again, there was a 33% growth suppression in the 33a+ line. The differences between the induced and uninduced cells were progressively
Figure 3
Effect of ectopic inducible p18 expression on cell growth. KMS12 cells, pMth (vector only) and 33a (pMth-p18 vector transfected) cells were plated in duplicate at a density of 1 × 10 5 /ml in 24-well plates. ZnCl 2 was added to the growth medium after 24 h to induce p18 expression. Following 24 and 48 h of Zn exposure cells were harvested and 100 l aliquots were counted by trypan blue exclusion for viable cell number. −, no ZnCl 2 added; +, 120 Ml ZnCl 2 added.
Leukemia larger at 48 h (Table 2) . When the cells were exposed to ZnCl 2 for 5 days, the 33a+ line cell number was reduced to 10-15% of the controls (data not shown). This observed decrease in the rate of cell growth may represent either cell cycle arrest, induction of apoptosis, or both. These results confirm the function of CDKI p18 as a negative growth regulator of cell cycle capable of inducing cell growth inhibition. Table 2 Effect of ectopic inducible p18 expression on metabolically active cells measured by MTS color development assay 
Leukemia
Apoptosis analysis
To discern whether the p18-induced growth inhibition was due to G1 phase cell cycle arrest or apoptosis, DNA was assayed by flow cytometry after propidium iodine staining. Inducible p18 expression did not cause significant accumulation of cells in G1 phase compared to the negative controls. However, in the presence of ZnCl 2 there was a significant increase in sub 2n cells in the 33a+ line which was more pronounced at 48 h, potentially reflecting a significant number of cells undergoing apoptosis (data not shown).
The generation of low molecular weight DNA fragmentation is a hallmark of apoptosis. When the p18 gene was induced for 18, 36, and 60 h, DNA isolated from the 33a+ cell line exhibited a characteristic apoptotic DNA fragmentation ladder when resolved by 1% agarose gel electrophoresis ( Figure 4 ). As we have found that Flavopiridol (Fp) treatment of KMS12 cells at a concentration of 600 nM for 24 h leads to DNA fragmentation (unpublished data), we used Fp-treated KMS12 cells as a positive control for apoptosis and the DNA ladder. KMS12 and 33a− cell lines showed no appreciable DNA fragmentation under the same conditions. To quantify the extent of apoptosis we examined DNA histograms of induced p18 as well as appropriate controls by flow cytometry at 24 h (Table 3 ). There were 36% apoptotic cells in the 33a+ cells, whereas in parental KMS12 and the vector-transfected pMth-Neo cells (with and without zinc exposure) it ranged from 7 to 13%, suggesting that p18 induction is associated with activation of apoptotic pathways. 
Discussion
In a subset of MM (ෂ20-25%), the translocation t(11;14) (q13;q32) results in cyclin D1 overexpression. 15 Several additional non-random molecular abnormalities have been described involving BCL2, C-MYC, RAS, p53, and pRb and correlated with poor clinical prognosis. However, these molecular changes have not been correlated with various stages of disease progression. Cyclin D1 overexpression along with loss-of-function mutations of p53 and pRb genes are consistent with the deregulation of normal cell cycle control, particularly at the G1-S phase transition. Virtually all members of the Rb pathway have been implicated pathogenetically in various forms of hematologic malignancies and other cancers; for example, CDKI p16 is deleted in some ALL, and in some MCL deletions of p16 or p18 coexist along with cyclin D1 overexpression. 29, 31 In the present study, we have characterized CDKI p15/p16 and p18 deletions in cyclin D1-overexpressing and nonexpressing MM cell lines. Homozygous p18 deletion was present in five lines, with a single p18 allele deleted in the FLAM 76 line (data not shown). Some of these deletions coexisted with hemizygous p16 deletion and suggest a selection advantage for concomitant cyclin D1 overexpression and deletion of one or more CDK inhibitors, potentially contributing to cell transformation and enhanced cell proliferation. p18 gene deletions and rearrangements have been identified in MCL and MM 21, 28, 29 but not in other neoplasms, [22] [23] [24] [25] [26] [27] supporting a possible role of this CDKI in MCL and myeloma pathogenesis. At this point, it is unknown whether p18 deletions in MM tumor cell lines represent an epiphenomenon of the cell culture process, although there is a report of such deletion in primary MM and in childhood T cell ALL samples. 21, 26 It is also unknown whether additional loss-offunction mutations including gene hypermethylation or point mutations are operative in MM or other human malignancies; p18 was inactivated by a point mutation in BT-20 human breast cancer cells rendering it deficient in suppressing cell growth. 32 In view of the high frequency of p18 deletions in MM cell lines, we investigated the significance of p18 inactivation by replacing its biologic function in a human myeloma cell line. Our data demonstrate that inducible ectopic p18 protein is indistinguishable from the constitutively expressed protein and inhibited cell proliferation, consistent with the reported functions of p18. 9, 10 We also found that ectopic expression of p18 in KMS12 cells induced apoptotic cell death and DNA fragmentation, suggesting that an efficient block of the cyclin D1/CDK/pRb pathway in MM could be a crucial step to induce tumor regression via apoptotic cell death. All five of the p18-expressing KMS12 clones generated showed inhibition of proliferation in vitro despite varying levels of ectopic p18 expression. Clone 33a, which had 10-to 20-fold higher p18 expression than exponentially growing Granta cells, was proapoptotic. However, this proapoptotic effect may be nonphysiologic given the high levels of induced p18. In IgG-bearing human lymphoblastoid cells, IL-6-induced p18 expression correlates with cell cycle arrest, terminal differentiation and cell death. 13 P18 is highly expressed during myogenic differentiation, potentially mediating accompanying growth arrest by CDK4/CDK6 inhibition. 33 Thus, p18 appears to be a critical element in both differentiation and proliferation pathways and may serve as a marker for treatment response or as a target for new therapeutic approaches in MM.
In summary, we report frequent p18 deletions in both cyclin D1-positive and -negative MM cell lines. These findings suggest a growth advantage to the cell, potentially leading to enhanced cell proliferation. Information on LOF mutations/deletions of CDKIs and other tumor suppressor genes may provide molecular markers for disease stage, prognosis and perhaps therapeutic response. Ectopic p18 expression suggests that this gene may play a vital role in inhibiting cell proliferation and promoting cell death in human myeloma. Furthermore, replacing p18/CDKI function via gene therapeutic or pharmacologic techniques may provide potentially new avenues for therapy of this presently incurable neoplasm.
